Biodexa Pharmaceuticals PLC
13F holders, Q3 2024 (September 30)7holders −5
1new positions
6sold out
$0.28avg. 13F price*
At the end of Q3 2024, 7 institutions reported holding Biodexa Pharmaceuticals PLC in their 13F filings, down 5 from Q2 2024. 1 opened new positions and 6 sold out. The largest holders were UBS Group AG ($72K), Two Sigma Securities, LLC ($9K) and Morgan Stanley ($4K).
- Company
- Biodexa Pharmaceuticals PLC
- CUSIP
- 59564R708
- Latest filing quarter
- Q3 2024
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $0 |
| Exits | 6 | $101K |
All 13F filers, Q2 2024 → Q3 2024: 275,131 shares bought and 116,880 shares sold, net +158,251 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 7 holders
| UBS Group AG | 0.00% | Add +2455.2% | 255,446 | $72K |
| Two Sigma Securities, LLC | 0.00% | Add +58.5% | 32,577 | $9K |
| Morgan Stanley | 0.00% | Add +89400.0% | 14,320 | $4K |
| Rhumbline Advisers | 0.00% | Add +122.8% | 6,038 | $2K |
| Contravisory Investment Management, Inc. | 0.00% | No change | 1,000 | $282 |
| GAMMA Investing LLC | 0.00% | Reduce -92.6% | 287 | $81 |
| Hantz Financial Services, Inc. | 0.00% | New | 30 | $0 |
"% of holder's portfolio" is BIODEXA PHARMACEUTICALS PLC's weight in each manager's 13F, not the share of Biodexa Pharmaceuticals PLC the manager owns.